Kris Iyer, Chief Scientific Officer at Spring Bank Pharmaceuticals, to give a presentation titled “Small Molecule Nucleic Acid Hybrids – A Novel Platform for Small Molecule Drug Discovery” at the Inaugural Nucleic Acid Research and Development Conference, June 29 & 20, 2014 in San Diego, CA.
PR-Inside.com: 2014-04-02 05:23:51
Radhakrishnan Iyer, (Kris) Ph.D. FRSC., is a widely recognized innovator in the fields of nucleic acid chemistry, bioorganic chemistry and pharmaceutical sciences. He has been the Principal Investigator for multiple NIH grants for the development of drugs against Hepatitis viruses. Previously, Kris was the co-founder and VP of Discovery of Origenix Technologies, Inc., where he directed a team of 30 scientists in chemistry and biology and was instrumental in advancing several programs from discovery to clinical development. He was an Associate Director of the Discovery program and Technology Development at Hybridon, Inc.
Previously, Kris was a Professor of Medicinal Chemistry at the University of Bombay, and held Visiting Scientist positions at the University of Texas, M. D. Anderson Cancer Center and at the CBER at FDA/NIH. He received his B.Sc. (Hons) in chemistry, B.Sc. (Tech.), and M.Sc. (Tech.) degrees in Pharmaceuticals and Fine Chemicals from the University of Bombay and Ph.D. in Pharmaceutical Sciences from the University of the Pacific, Stockton, California. Kris carried out postdoctoral work at the Oak Ridge National Laboratory and at the Johns Hopkins University. He has authored over 100 scientific papers, books on organic synthesis and is an inventor of more than 100 filed and issued patents.
For more information, please visit www.gtcbio.com/nucleicacid/agenda